ARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Inc reported a quarterly adjusted loss of 46 cents per share for the quarter ended June 30, compared to a loss of 13 cents per share in the same quarter last year. Revenue surged 3,043.4% to $15.72 million, exceeding analyst expectations of $13.78 million. The company reported a total loss of $44.88 million. Despite a 4.5% drop in shares this quarter, they have gained 57.9% year-to-date. Analysts maintain a "strong buy" rating, with a median 12-month price target of $30.00, 44.5% above the last closing price of $16.66.
- ARS Pharmaceuticals Inc (SPRY.OQ) reported a quarterly adjusted loss of 46 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -13 cents. The mean expectation of six analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -66 cents to -37 cents per share.
- Revenue rose 3,043.4% to $15.72 million from a year ago; analysts expected $13.78 million.
- ARS Pharmaceuticals Inc’s reported EPS for the quarter was a loss of 46 cents.
- The company reported a quarterly loss of $44.88 million.
- ARS Pharmaceuticals Inc shares had fallen by 4.5% this quarter and gained 57.9% so far this year. FORECAST CHANGES
- The mean earnings estimate of analysts had risen by about 0.4% in the last three months.
- In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS
- The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 6 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” The average consensus recommendation for the biotechnology & medical research peer group is “buy.”
- Wall Street’s median 12-month price target for ARS Pharmaceuticals Inc is $30.00, about 44.5% above its last closing price of $16.66 This summary was machine generated from LSEG data August 13 at 01:30 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2025 -0.47 -0.46 Beat
Mar. 31 2025 -0.35 -0.35 Met
Dec. 31 2024 -0.14 0.49 Beat
Sep. 30 2024 -0.15 -0.20 Missed
